## Ceshi Chen

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/668960/publications.pdf

Version: 2024-02-01

112 papers	5,350 citations	40 h-index	98798 67 g-index
113	113	113	6747
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	YB-1 is a positive regulator of KLF5 transcription factor in basal-like breast cancer. Cell Death and Differentiation, 2022, 29, 1283-1295.	11.2	23
2	Histone Deacetylase Inhibitors (HDACi) Promote KLF5 Ubiquitination and Degradation in Basal-like Breast Cancer. International Journal of Biological Sciences, 2022, 18, 2104-2115.	6.4	10
3	PRMT5 regulates RNA m6A demethylation for doxorubicin sensitivity in breast cancer. Molecular Therapy, 2022, 30, 2603-2617.	8.2	49
4	STAMBPL1 promotes breast cancer cell resistance to cisplatin partially by stabilizing MKP-1 expression. Oncogene, 2022, 41, 2265-2274.	5.9	7
5	Rab13 Sustains Breast Cancer Stem Cells by Supporting Tumor–Stroma Cross-talk. Cancer Research, 2022, 82, 2124-2140.	0.9	8
6	YB-1 as an Oncoprotein: Functions, Regulation, Post-Translational Modifications, and Targeted Therapy. Cells, 2022, 11, 1217.	4.1	18
7	A feedforward circuit between KLF5 and IncRNA KPRT4 contributes to basal-like breast cancer. Cancer Letters, 2022, 534, 215618.	7.2	5
8	Progress of Breast Cancer basic research in China. International Journal of Biological Sciences, 2021, 17, 2069-2079.	6.4	43
9	Isochromanoindolenines suppress triple-negative breast cancer cell proliferation partially via inhibiting Akt activation. International Journal of Biological Sciences, 2021, 17, 986-994.	6.4	2
10	Glucose-6-phosphate dehydrogenase neutralizes stresses by supporting reductive glutamine metabolism and AMPK activation. Signal Transduction and Targeted Therapy, 2021, 6, 46.	17.1	6
11	Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. Frontiers in Pharmacology, 2021, 12, 628690.	3 <b>.</b> 5	165
12	EphA2: A promising therapeutic target in breast cancer. Journal of Genetics and Genomics, 2021, 48, 261-267.	3.9	23
13	Targeting ubiquitin conjugating enzyme UbcH5b by a triterpenoid PC3-15 from Schisandra plants sensitizes triple-negative breast cancer cells to lapatinib. Cancer Letters, 2021, 504, 125-136.	7.2	10
14	Naturally-occurring spinosyn A and its derivatives function as argininosuccinate synthase activator and tumor inhibitor. Nature Communications, 2021, 12, 2263.	12.8	28
15	The roles and regulation of the KLF5 transcription factor in cancers. Cancer Science, 2021, 112, 2097-2117.	3.9	53
16	Cyst(e)ine in nutrition formulation promotes colon cancer growth and chemoresistance by activating mTORC1 and scavenging ROS. Signal Transduction and Targeted Therapy, 2021, 6, 188.	17.1	22
17	Arginine methyltransferase PRMT5 methylates and stabilizes KLF5 via decreasing its phosphorylation and ubiquitination to promote basal-like breast cancer. Cell Death and Differentiation, 2021, 28, 2931-2945.	11.2	24
18	Characterization of tree shrew telomeres and telomerase. Journal of Genetics and Genomics, 2021, 48, 631-639.	3.9	2

#	Article	IF	CITATIONS
19	The methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism is associated with breast cancer subtype susceptibility in southwestern China. PLoS ONE, 2021, 16, e0254267.	2.5	3
20	KAT6A Acetylation of SMAD3 Regulates Myeloidâ€Derived Suppressor Cell Recruitment, Metastasis, and Immunotherapy in Tripleâ€Negative Breast Cancer. Advanced Science, 2021, 8, e2100014.	11.2	30
21	Lossâ€ofâ€Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia. Hepatology, 2021, 74, 1461-1479.	7.3	53
22	KLF5-induced IncRNA IGFL2-AS1 promotes basal-like breast cancer cell growth and survival by upregulating the expression of IGFL1. Cancer Letters, 2021, 515, 49-62.	7.2	17
23	The role of E3 ubiquitin ligase HECTD3 in cancer and beyond. Cellular and Molecular Life Sciences, 2020, 77, 1483-1495.	5.4	18
24	Cancer progression is mediated by proline catabolism in non-small cell lung cancer. Oncogene, 2020, 39, 2358-2376.	5.9	51
25	Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer. Frontiers in Pharmacology, 2020, 11, 580251.	3.5	38
26	Inhibiting both proline biosynthesis and lipogenesis synergistically suppresses tumor growth. Journal of Experimental Medicine, 2020, 217, .	8.5	37
27	A functional missense variant in ITIH3 affects protein expression and neurodevelopment and confers schizophrenia risk in the Han Chinese population. Journal of Genetics and Genomics, 2020, 47, 233-248.	3.9	10
28	SGCE Promotes Breast Cancer Stem Cells by Stabilizing EGFR. Advanced Science, 2020, 7, 1903700.	11.2	38
29	Roles of RNF126 and BCA2 E3 ubiquitin ligases in DNA damage repair signaling and targeted cancer therapy. Pharmacological Research, 2020, 155, 104748.	7.1	14
30	TNF-α increases breast cancer stem-like cells through up-regulating TAZ expression via the non-canonical NF-ÎB pathway. Scientific Reports, 2020, 10, 1804.	3.3	47
31	Mifepristone Derivative FZU-00,003 Suppresses Triple-negative Breast Cancer Cell Growth partially via miR-153-KLF5 axis. International Journal of Biological Sciences, 2020, 16, 611-619.	6.4	14
32	A new Schiff base copper(II) complex induces cancer cell growth inhibition and apoptosis by multiple mechanisms. Journal of Inorganic Biochemistry, 2020, 208, 111103.	3.5	11
33	Pyrrolo [3,4-b]-quinolin-9-amine compound FZU-0038-056 suppresses triple-negative breast cancer partially through inhibiting the expression of Bcl-2. Aging, 2020, 12, 9621-9632.	3.1	2
34	Econazole nitrate reversed the resistance of breast cancer cells to Adriamycin through inhibiting the PI3K/AKT signaling pathway. American Journal of Cancer Research, 2020, 10, 263-274.	1.4	6
35	Heterogeneity and Subtyping of Triple-Negative Breast Cancer. , 2020, , 21-40.		0
36	Comprehensive analysis of long noncoding RNAs and mRNAs expression profiles and functional networks during chondrogenic differentiation of murine ATDC5 cells. Acta Biochimica Et Biophysica Sinica, 2019, 51, 778-790.	2.0	1

#	Article	IF	CITATIONS
37	Glucocorticoid Receptor Signaling Activates TEAD4 to Promote Breast Cancer Progression. Cancer Research, 2019, 79, 4399-4411.	0.9	75
38	llamycin E, a natural product of marine actinomycete, inhibits triple-negative breast cancer partially through ER stress-CHOP-Bcl-2. International Journal of Biological Sciences, 2019, 15, 1723-1732.	6.4	39
39	Inhibition of super enhancer downregulates the expression of KLF5 in basal-like breast cancers. International Journal of Biological Sciences, 2019, 15, 1733-1742.	6.4	25
40	USP3 promotes breast cancer cell proliferation by deubiquitinating KLF5. Journal of Biological Chemistry, 2019, 294, 17837-17847.	3.4	49
41	A thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3. Journal of Biological Chemistry, 2019, 294, 17471-17486.	3.4	20
42	Tumor Suppression of Ras GTPase-Activating Protein RASA5 through Antagonizing Ras Signaling Perturbation in Carcinomas. IScience, 2019, 21, 1-18.	4.1	12
43	HDAC inhibitors induce proline dehydrogenase (POX) transcription and anti-apoptotic autophagy in triple negative breast cancer. Acta Biochimica Et Biophysica Sinica, 2019, 51, 1064-1070.	2.0	20
44	Genetic basis of ruminant headgear and rapid antler regeneration. Science, 2019, 364, .	12.6	121
45	The antipsychotic agent flupentixol is a new PI3K inhibitor and potential anticancer drug for lung cancer. International Journal of Biological Sciences, 2019, 15, 1523-1532.	6.4	12
46	CUL7 promotes cancer cell survival through promoting Caspaseâ€8 ubiquitination. International Journal of Cancer, 2019, 145, 1371-1381.	5.1	18
47	A novel synthetic ursolic acid derivative inhibits growth and induces apoptosis in breast cancer cell lines. Oncology Letters, 2018, 15, 2323-2329.	1.8	11
48	Discovery of novel mifepristone derivatives via suppressing KLF5 expression for the treatment of triple-negative breast cancer. European Journal of Medicinal Chemistry, 2018, 146, 354-367.	5.5	16
49	Hypoxia induces miR-153 through the IRE1α-XBP1 pathway to fine tune the HIF1α/VEGFA axis in breast cancer angiogenesis. Oncogene, 2018, 37, 1961-1975.	5.9	107
50	Mithramycin A suppresses basal triple-negative breast cancer cell survival partially via down-regulating Kr $\tilde{A}^{1}\!4$ ppel-like factor 5 transcription by Sp1. Scientific Reports, 2018, 8, 1138.	3.3	30
51	RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clinical Cancer Research, 2018, 24, 1629-1643.	7.0	30
52	Synthesis and structure–activity relationship studies of MI-2 analogues as MALT1 inhibitors. Bioorganic and Medicinal Chemistry, 2018, 26, 3321-3344.	3.0	13
53	EZH2 induces the expression of miR-1301 as a negative feedback control mechanism in triple negative breast cancer. Acta Biochimica Et Biophysica Sinica, 2018, 50, 693-700.	2.0	7
54	miR-153 inhibits the migration and the tube formation of endothelial cells by blocking the paracrine of angiopoietin 1 in breast cancer cells. Angiogenesis, 2018, 21, 849-860.	7.2	43

#	Article	IF	Citations
55	CC chemokine receptor 7 promotes triple-negative breast cancer growth and metastasis. Acta Biochimica Et Biophysica Sinica, 2018, 50, 835-842.	2.0	15
56	Krýppleâ€like factor 5 is essential for mammary gland development and tumorigenesis. Journal of Pathology, 2018, 246, 497-507.	4.5	25
57	The roles of <scp>TNFAIP</scp> 2 in cancers and infectious diseases. Journal of Cellular and Molecular Medicine, 2018, 22, 5188-5195.	3.6	65
58	HECTD3 mediates TRAF3 polyubiquitination and type I interferon induction during bacterial infection. Journal of Clinical Investigation, 2018, 128, 4148-4162.	8.2	44
59	Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discovery, 2017, 3, 17010.	6.7	106
60	Ursolic acid derivative FZU-03,010 inhibits STAT3 and induces cell cycle arrest and apoptosis in renal and breast cancer cells. Acta Biochimica Et Biophysica Sinica, 2017, 49, 367-373.	2.0	25
61	Econazole nitrate inhibits PI3K activity and promotes apoptosis in lung cancer cells. Scientific Reports, 2017, 7, 17987.	3.3	16
62	YD277 Suppresses Triple-Negative Breast Cancer Partially Through Activating the Endoplasmic Reticulum Stress Pathway. Theranostics, 2017, 7, 2339-2349.	10.0	23
63	æ'é⅓©——ä½œä¸ºä¸€ç§æ–°é¢–çš"é≹人çµé•¿ç±»å®žéºŒç–¾ç—…动物模型. Zoo	log <b>ica</b> l Res	sea <b>sc</b> h, 2017,
64	miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5. PLoS ONE, 2017, 12, e0176395.	2.5	37
65	Characterization and phylogenetic analysis of Krýppel-like transcription factor (KLF) gene family in tree shrews ( <i>Tupaia belangeri chinensis</i> ). Oncotarget, 2017, 8, 16325-16339.	1.8	19
66	Dexamethasone induces docetaxel and cisplatin resistance partially through up-regulating Kr $ ilde{A}$ -/4ppel-like factor 5 in triple-negative breast cancer. Oncotarget, 2017, 8, 11555-11565.	1.8	39
67	Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression. Theranostics, 2016, 6, 533-544.	10.0	103
68	The role of semaphorin 4D in tumor development and angiogenesis in human breast cancer. OncoTargets and Therapy, 2016, Volume 9, 5737-5750.	2.0	25
69	KHF16 is a Leading Structure from <i>Cimicifuga foetida</i> that Suppresses Breast Cancer Partially by Inhibiting the NF-I <sup>o</sup> B Signaling Pathway. Theranostics, 2016, 6, 875-886.	10.0	27
70	A new oridonin analog suppresses triple-negative breast cancer cells and tumor growth via the induction of death receptor 5. Cancer Letters, 2016, 380, 393-402.	7.2	53
71	Generation and characterization of a breast carcinoma model by <scp>PyMT</scp> overexpression in mammary epithelial cells of tree shrew, an animal close to primates in evolution. International Journal of Cancer, 2016, 138, 642-651.	5.1	34
72	Transforming growth factor-beta increases breast cancer stem cell population partially through upregulating PMEPA1 expression. Acta Biochimica Et Biophysica Sinica, 2016, 48, 194-201.	2.0	26

#	Article	IF	Citations
73	Ataxin-3 like (ATXN3L), a member of the Josephin family of deubiquitinating enzymes, promotes breast cancer proliferation by deubiquitinating Krüppel-like factor 5 (KLF5). Oncotarget, 2015, 6, 21369-21378.	1.8	39
74	Tobacco carcinogen NNK-induced lung cancer animal models and associated carcinogenic mechanisms. Acta Biochimica Et Biophysica Sinica, 2015, 47, 477-487.	2.0	41
75	BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5. Nature Communications, 2015, 6, 8471.	12.8	148
76	Hippo pathway in mammary gland development and breast cancer. Acta Biochimica Et Biophysica Sinica, 2015, 47, 53-59.	2.0	61
77	The interplay between TEAD4 and KLF5 promotes breast cancer partially through inhibiting the transcription of <i>p27</i> Kip1. Oncotarget, 2015, 6, 17685-17697.	1.8	73
78	Cucurbitacin E Induces Cell Cycle G2/M Phase Arrest and Apoptosis in Triple Negative Breast Cancer. PLoS ONE, 2014, 9, e103760.	2.5	60
79	Tongshu Capsule Down-Regulates the Expression of Estrogen Receptor $\hat{l}_{\pm}$ and Suppresses Human Breast Cancer Cell Proliferation. PLoS ONE, 2014, 9, e104261.	2.5	4
80	PTEN/PIK3CA genes are frequently mutated in spontaneous and medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumours of tree shrews. European Journal of Cancer, 2014, 50, 3230-3242.	2.8	22
81	WWOX suppresses KLF5 expression and breast cancer cell growth. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 511-6.	2.2	1
82	The HECTD3 E3 Ubiquitin Ligase Suppresses Cisplatin-Induced Apoptosis via Stabilizing MALT1. Neoplasia, 2013, 15, 39-IN15.	5.3	36
83	RNF115/BCA2 E3 Ubiquitin Ligase Promotes Breast Cancer Cell Proliferation through Targeting p21Waf1/Cip1 for Ubiquitin-Mediated Degradation. Neoplasia, 2013, 15, 1028-1035.	5.3	30
84	Role of KLF5 in Hormonal Signaling and Breast Cancer Development. Vitamins and Hormones, 2013, 93, 213-225.	1.7	16
85	E3 Ubiquitin Ligase RNF126 Promotes Cancer Cell Proliferation by Targeting the Tumor Suppressor p21 for Ubiquitin-Mediated Degradation. Cancer Research, 2013, 73, 385-394.	0.9	64
86	Kr $ ilde{A}^{1}\!\!/\!\!4$ ppel-like Factor 5 Transcription Factor Promotes Microsomal Prostaglandin E2 Synthase 1 Gene Transcription in Breast Cancer. Journal of Biological Chemistry, 2013, 288, 26731-26740.	3.4	41
87	TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis. Carcinogenesis, 2012, 33, 59-67.	2.8	84
88	The Induction of Yes-Associated Protein Expression After Arterial Injury Is Crucial for Smooth Muscle Phenotypic Modulation and Neointima Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 2662-2669.	2.4	94
89	YAP Promotes Breast Cell Proliferation and Survival Partially through Stabilizing the KLF5 Transcription Factor. American Journal of Pathology, 2012, 180, 2452-2461.	3.8	112
90	WWP1: a versatile ubiquitin E3 ligase in signaling and diseases. Cellular and Molecular Life Sciences, 2012, 69, 1425-1434.	5.4	94

#	Article	IF	CITATIONS
91	The WWP1 ubiquitin E3 ligase increases TRAIL resistance in breast cancer. International Journal of Cancer, 2012, 130, 1504-1510.	5.1	25
92	PMEPA1 promotes androgen receptorâ€negative prostate cell proliferation through suppressing the Smad3/4–câ€Myc–p21\$^{{m Cip1}}\$ signaling pathway. Journal of Pathology, 2011, 223, 683-694.	4.5	57
93	The Induction of KLF5 Transcription Factor by Progesterone Contributes to Progesterone-Induced Breast Cancer Cell Proliferation and Dedifferentiation. Molecular Endocrinology, 2011, 25, 1137-1144.	3.7	55
94	Reactive oxygen species control senescenceâ€associated matrix metalloproteinaseâ€1 through câ€Junâ€Nâ€terminal kinase. Journal of Cellular Physiology, 2010, 225, 52-62.	4.1	66
95	The Fbw7 Tumor Suppressor Targets KLF5 for Ubiquitin-Mediated Degradation and Suppresses Breast Cell Proliferation. Cancer Research, 2010, 70, 4728-4738.	0.9	134
96	Regulation of Kr $\tilde{A}^{1}\!4$ pple-Like Factor 5 by Targeted Protein Degradation. Methods in Molecular Biology, 2010, 647, 267-277.	0.9	7
97	KLF5 Promotes Breast Cell Survival Partially through Fibroblast Growth Factor-binding Protein 1-pERK-mediated Dual Specificity MKP-1 Protein Phosphorylation and Stabilization. Journal of Biological Chemistry, 2009, 284, 16791-16798.	3.4	75
98	Overexpression of WWP1 is associated with the estrogen receptor and insulinâ€ike growth factor receptor 1 in breast carcinoma. International Journal of Cancer, 2009, 124, 2829-2836.	5.1	43
99	Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases. Cellular and Molecular Life Sciences, 2009, 66, 2691-2706.	5.4	234
100	Proteasomal degradation of the KLF5 transcription factor through a ubiquitin-independent pathway. FEBS Letters, 2007, 581, 1124-1130.	2.8	35
101	The amplifiedWWP1 gene is a potential molecular target in breast cancer. International Journal of Cancer, 2007, 121, 80-87.	5.1	119
102	The Nedd4-like family of E3 ubiquitin ligases and cancer. Cancer and Metastasis Reviews, 2007, 26, 587-604.	5.9	189
103	KLF5 promotes cell proliferation and tumorigenesis through gene regulationin the TSU-Pr1 human bladder cancer cell line. International Journal of Cancer, 2006, 118, 1346-1355.	5.1	136
104	Genetic and Expression Aberrations of E3 Ubiquitin Ligases in Human Breast Cancer. Molecular Cancer Research, 2006, 4, 695-707.	3.4	59
105	KLF5 Interacts with p53 in Regulating Survivin Expression in Acute Lymphoblastic Leukemia. Journal of Biological Chemistry, 2006, 281, 14711-14718.	3.4	101
106	Ubiquitin–proteasome degradation of KLF5 transcription factor in cancer and untransformed epithelial cells. Oncogene, 2005, 24, 3319-3327.	5.9	128
107	Human Kruppel-like Factor 5 Is a Target of the E3 Ubiquitin Ligase WWP1 for Proteolysis in Epithelial Cells. Journal of Biological Chemistry, 2005, 280, 41553-41561.	3.4	127
108	Regulation of KLF5 involves the Sp1 transcription factor in human epithelial cells. Gene, 2004, 330, 133-142.	2,2	36

#	ARTICLE	IF	CITATION
109	<i>KLF5</i> is frequently deleted and downâ€regulated but rarely mutated in prostate cancer. Prostate, 2003, 55, 81-88.	2.3	125
110	Deletion, Mutation, and Loss of Expression of KLF6 in Human Prostate Cancer. American Journal of Pathology, 2003, 162, 1349-1354.	3.8	137
111	A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene, 2002, 21, 6567-6572.	5.9	135
112	Defining a common region of deletion at 13q21 in human cancers. Genes Chromosomes and Cancer, 2001, 31, 333-344.	2.8	33